var data={"title":"Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5654?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=antithymocyte-globulin-rabbit-derived-thymoglobulin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Antithymocyte globulin (rabbit derived, Thymoglobulin): Patient drug information&quot;</a> and <a href=\"topic.htm?path=antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Antithymocyte globulin (rabbit derived, Thymoglobulin): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708632\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Anti-thymocyte globulin should only be used by physicians experienced in immunosuppressive therapy in transplantation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135993\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Thymoglobulin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20858411\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Thymoglobulin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136005\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Immune Globulin;</li>\n      <li>\n        Immunosuppressant Agent;</li>\n      <li>\n        Polyclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135994\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premedicate with corticosteroids, acetaminophen, and/or an antihistamine 1 hour prior to infusion to reduce the incidence and severity of infusion-related reactions. Administer antifungal and antibacterial prophylaxis therapy if clinically indicated. Antiviral prophylaxis is recommended in patients who are CMV-seropositive at the time of transplant and for CMV-seronegative patients scheduled to receive a kidney from a CMV-seropositive donor.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal transplant (acute rejection treatment):</b> IV: 1.5 mg/kg/day for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal transplant (induction therapy):</b> IV: 1.5 mg/kg/day for 4 to 7 days; the first dose should be administered prior to reperfusion of the donor kidney</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Off-label induction dosing:</i></b> IV: 1.5 mg/kg once daily for 5 to 7 days (Brennan 1999; Brennan 2006; Hardinger 2008) <b>or</b> 1 mg/kg once daily for 3 to 6 days (Goggins 2003); alternative dosing strategies with higher doses for shorter durations such as 2 mg/kg once daily for 3 days have also been recommended (Hardinger 2010); dosing based on peripheral blood CD3+ lymphocyte counts has also been described with an initial dose of 1.5 mg/kg followed by repeat doses when CD3+ count is &gt;20 cells/mm<sup>3</sup> (Peddi 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic graft-versus-host disease </b>\n      <b>(prevention) (off-label use): </b>IV: 0.5 mg/kg administered 2 days prior to transplant and 2 mg/kg administered 1 day before and 1 day after transplant (Walker 2016) <b>or</b> 2.5 mg/kg once daily for 3 days beginning 3 days prior to transplant (Ruutu 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart transplant (induction therapy in high risk patients) (off-label use):</b> IV: 1 to 1.5 mg/kg once daily for up to 7 days (Zuckermann 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart transplant (acute cellular rejection, treatment) (off-label use):</b> IV: 0.75 to 1.5 mg/kg/day for 5 to 14 days (ISHLT [Costanzo 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intestinal and multivisceral </b>\n      <b>transplantation (induction therapy) (off-label use): </b>IV: 2 mg/kg/day on postoperative days 0, 2, 4, 6, and 8 (in combination with rituximab) (Vianna 2008). Additional trials data may be necessary to further define the role of antithymocyte globulin (rabbit) in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lung transplant (induction therapy) (off-label use): </b>IV: 1.5 mg/kg/day for 3 days; the first dose was administered within 24 hours of transplantation (Palmer 1999; Hartwig 2008). Additional trails may be necessary to further define the role of antithymocyte globulin (rabbit) for prevention of rejection after lung transplant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lung transplant (persistent acute cellular rejection, treatment) (off-label use): </b>IV: Pulse treatments have been used to manage persistent acute cellular rejection (Martinu 2000). Additional data may be necessary to further define the role of antithymocyte globulin (rabbit) in treatment of acute cellular rejection after lung transplantation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136002\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Antithymocyte globulin (rabbit derived, Thymoglobulin): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Renal transplant (induction therapy and acute rejection treatment):</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135995\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46276611\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46276612\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26416857\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity: </i>Utilize actual body weight (full weight) to calculate mg/kg dosing for hematopoietic stem cell transplant conditioning regimens (Bubalo 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F639201\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal transplantation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">WBC count 2,000 to 3,000 cells/mm<sup>3</sup> or platelet count 50,000 to 75,000 cells/mm<sup>3</sup>: Reduce dose by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">WBC count &lt;2,000 cells/mm<sup>3</sup> or platelet count &lt;50,000 cells/mm<sup>3</sup>: Consider discontinuing treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135985\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thymoglobulin: 25 mg (1 ea) [contains glycine, mannitol, sodium chloride]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135975\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135987\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse the first dose over at least 6 hours; subsequent doses may be infused over at least 4 hours. Infuse through a high-flow vein (central line). Administer through an in-line 0.22 micron filter. Premedication with corticosteroids, acetaminophen, and/or an antihistamine 1 hour prior to infusion may reduce the incidence and severity of infusion-related reactions. Reducing the infusion rate may minimize infusion reactions. Infusion rate may vary for off-label uses; refer to specific protocol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In renal transplantation, administration through a peripheral vein has been reported with the addition of 1,000 units heparin and 20 mg hydrocortisone (in 500 mL NS only) to decrease the risk of thrombosis and phlebitis (Marvin 2003; Trofe-Clark 2012). The first 2 doses were infused over 6 hours and subsequent doses were infused over 4 hours (Trofe-Clark 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135986\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal transplant rejection:</b> Prophylaxis and treatment of acute rejection in renal transplantation (in conjunction with concomitant immunosuppression)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In a multicenter, double-blind, randomized trial, antithymocyte globulin (rabbit) was shown to be superior to antithymocyte globulin (equine) in reversing acute rejection and preventing subsequent episodes (Gaber 1998). Based on data from studies (including 10 years follow up) comparing ATG (rabbit) to ATG (equine) for induction, ATG (rabbit) has emerged as the T-cell lymphocyte depleting induction therapy of choice over ATG (equine) in adult kidney transplantation due to its improved efficacy and lower incidence of acute rejection (Brennan 1999; Hardinger 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25721920\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chronic graft-versus-host disease (prevention); Heart transplant (induction therapy); Heart transplant (acute cellular rejection) (treatment); Intestinal and multivisceral transplantation (induction therapy); Lung transplant (induction therapy); Lung transplant (persistent acute cellular rejection) (treatment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9885364\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Antithymocyte globulin rabbit (Thymoglobulin) may be confused with antithymocyte globulin equine (Atgam)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135981\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (27% to 37%), tachycardia (23%), peripheral edema (20%), hypotension (10% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (55% to 57%), headache (27% to 40%), pain (26%), insomnia (12% to 20%), malaise (9% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (7% to 13%), diaphoresis (6% to 13%), acne vulgaris (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperkalemia (17% to 27%), hypokalemia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (17% to 38%), nausea (29% to 37%), diarrhea (20%), vomiting (20%), constipation (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (49% to 57%), thrombocytopenia (29% to 37%), leukocytosis (13%), anemia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (17%), cytomegalovirus disease (13%), sepsis (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (11% to 20%), arthralgia (15%), weakness (13%), back pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (15% to 28%), pulmonary disease (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (46%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (9%), edema (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Acidosis (9%), hypophosphatemia (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (10%), anorexia (6%), intestinal candidiasis (5%), gastritis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Malignant neoplasm (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Serum sickness (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes simplex infection (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Increased cough (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Drug overdose (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, blood coagulation disorder, cytokine release syndrome, decreased oxygen saturation, increased liver enzymes, infusion-related reaction, lymphadenopathy, lymphoproliferative disorder (posttransplant), malignant lymphoma, proteinuria, solid tumor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135990\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (allergy or anaphylaxis) to rabbit proteins or any component of the formulation; active acute or chronic infection which contraindicate additional immunosuppression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for drugs in this class is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135979\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Reversible leukopenia, neutropenia, thrombocytopenia, and lymphopenia may occur. Monitor blood counts. Leukopenia and/or thrombocytopenia may require dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity and fatal anaphylactic reactions have been reported. Stop infusion immediately if anaphylactic reaction occurs. Immediate treatment (including subcutaneous epinephrine and corticosteroids) should be available during infusion for management of hypersensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Severe infections (bacterial, fungal, viral and/or protozoal) may develop following concomitant use of immunosuppressants with antithymocyte globulin. Reactivation of infections (particularly CMV) and sepsis have been reported. Appropriate antiviral, antibacterial, antiprotozoal, and/or antifungal prophylaxis is recommended. Monitor closely for infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Release of cytokines by activated monocytes and lymphocytes may lead to cytokine release syndrome (CRS) during infusion; may cause serious cardiopulmonary events (sometimes fatal). Rapid infusion rates have been associated with CRS (case reports). Other infusion reaction symptoms, including flu-like symptoms (fever, chills, nausea, muscle/joint pain) may also occur. Local infusion site reactions (pain, swelling, skin redness) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Immunosuppressants, including antithymocyte globulins may increase the incidence of malignancies, including lymphoma, post-transplant lymphoproliferative disease (PTLD) or other malignancies; may be fatal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should not be immunized with attenuated live viral vaccines during or shortly after treatment; safety of immunization following therapy has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Disease-related concerns:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Liver transplantation induction: Antithymocyte globulin (rabbit) has been associated with increased adverse effects when used for induction in liver transplantation and should be used cautiously in this population (Boillot 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Initial dose must be administered over at least 6 hours into a high flow vein. Reducing the infusion rate (and prolonging the administration time) may minimize infusion reactions. May pretreat with an antipyretic, antihistamine, and/or corticosteroid.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should only be used by physicians experienced in immunosuppressive therapy in transplantation.</b> Maintenance immunosuppression may require dosage reduction. Medical surveillance is required during the infusion. Should be administered in combination with other immunosuppressants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product selection: Antithymocyte globulin (ATG) (rabbit) is available (based on region) in different product formulations, ATG-Thymoglobulin and ATG-Fresenius; the dosing differs among the formulations. Dosing of antithymocyte globulin (rabbit) also differs from dosing of other antithymocyte globulin products (eg, ATG [equine]); protein compositions and concentrations are different. Use caution to ensure dose prescribed is intended for product being administered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298764\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218046\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10026&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belatacept: Antithymocyte Globulin (Rabbit) may enhance the adverse/toxic effect of Belatacept. Specifically, the risk for venous thrombosis of the renal allograft may be increased.  Management: A 12-hour interval between administration of these 2 agents is suggested if these agents are to be used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F639176\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted. Females of reproductive potential should use effective contraception during and for at least 3 months following treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21098383\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">This product has not been evaluated in breastfeeding women and it is not known if antithymocyte globulin (rabbit) is present in breast milk. Because other immunoglobulins are present in breast milk, the manufacturer recommends that breastfeeding be discontinued during antithymocyte globulin (rabbit) therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135983\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Lymphocyte count (total lymphocyte and/or T-cell subset), CBC with differential and platelet count; vital signs during administration; signs and symptoms of infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Solid organ transplant:</i> Absolute CD3 count (cells/&micro;L) monitoring and CD3 based dosing has been considered in renal and heart transplant recipients. It may be beneficial in certain patient populations but is not routinely recommended or utilized. Dose adjustments have been recommended based on the CD3 count (Krasinska 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135978\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Antithymocyte globulin (rabbit) is a polyclonal antibody which appears to cause immunosuppression by acting on T-cell surface antigens and depleting CD4 lymphocytes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135989\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action (T-cell depletion): Within 24 hours (Hardinger 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Lymphopenia may persist for up to 1 year (Hardinger 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2 to 3 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322995\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Thymoglobulin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1): $957.96</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038531\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>ATG-Fresenius (CY);</li>\n      <li>ATG-Fresinius (EE, SE);</li>\n      <li>Thymoglobulin (DE);</li>\n      <li>Thymoglobuline (AT, AU, BG, BR, CH, CN, CZ, DK, FI, FR, GB, GR, HK, IE, IT, KR, LU, LV, MT, MY, NL, NO, PL, SG, SI, TH, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19877264\"></a>Boillot O, Seket B, Dumortier J, et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. <i>Liver Transpl</i>. 2009;15(11):1426-1434.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/19877264/pubmed\" target=\"_blank\" id=\"19877264\">19877264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17093248\"></a>Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. <i>N Engl J Med</i>. 2006;355(19):1967-1977.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/17093248/pubmed\" target=\"_blank\" id=\"17093248\">17093248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10221486\"></a>Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients [published correction appears in <i>Transplantation</i> 1999;67(10):1386]. <i>Transplantation</i>. 1999;67(7):1011-1018.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/10221486/pubmed\" target=\"_blank\" id=\"10221486\">10221486</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16670072\"></a>Broliden PA, Dahl IM, Hast R, et al, &ldquo;Antithymocyte Globulin and Cyclosporine A as Combination Therapy for Low-Risk Non-Sideroblastic Myelodysplastic Syndromes,&rdquo; <i>Haematologica</i>, 2006, 91(5):667-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/16670072/pubmed\" target=\"_blank\" id=\"16670072\">16670072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/24462742/pubmed\" target=\"_blank\" id=\"24462742\">24462742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12660513\"></a>Charpentier B, Rostaing L, Berthoux F, et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. <i>Transplantation</i>. 2003;75(6):844-851.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/12660513/pubmed\" target=\"_blank\" id=\"12660513\">12660513</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costanzo MR, Dipchand A, Starling R, et al; International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2010;29(8):914-956. doi: 10.1016/j.healun.2010.05.034.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/20643330/pubmed\" target=\"_blank\" id=\"20643330\">20643330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9679818\"></a>Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. <i>Transplantation</i>. 1998;66(1):29-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/9679818/pubmed\" target=\"_blank\" id=\"9679818\">9679818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14501856\"></a>Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. <i>Transplantation</i>. 2003;76(5):798-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/14501856/pubmed\" target=\"_blank\" id=\"14501856\">14501856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17125438\"></a>Hardinger KL, &ldquo;Rabbit Antithymocyte Globulin Induction Therapy in Adult Renal Transplantation,&rdquo; <i>Pharmacotherapy</i>, 2006, 26(12):1771-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/17125438/pubmed\" target=\"_blank\" id=\"17125438\">17125438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21076531\"></a>Hardinger KL, Rasu RS, Skelton R, Miller BW, Brennan DC. Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days? <i>J Transplant</i>. 2010;2010:957549.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/21076531/pubmed\" target=\"_blank\" id=\"21076531\">21076531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18852661\"></a>Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. <i>Transplantation</i>. 2008;86(7):947-952.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/18852661/pubmed\" target=\"_blank\" id=\"18852661\">18852661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18442722\"></a>Hartwig MG, Snyder LD, Appel JZ 3rd, et al. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. <i>J Heart Lung Transplant</i>. 2008;27(5):547-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/18442722/pubmed\" target=\"_blank\" id=\"18442722\">18442722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11981432\"></a>Krasinskas AM, Kreisel D, Acker MA, et al. CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. <i>Transplantation</i>. 2002;73(8):1339-1341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/11981432/pubmed\" target=\"_blank\" id=\"11981432\">11981432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26735993\"></a>Kr&ouml;ger N, Solano C, Wolschke C, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. <i>N Engl J Med</i>. 2016;374(1):43-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/26735993/pubmed\" target=\"_blank\" id=\"26735993\">26735993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20354931\"></a>Martinu T, Howell DN, Palmer SM. Acute cellular rejection and humoral sensitization in lung transplant recipients. <i>Semin Respir Crit Care Med</i>. 2010;31(2):179-188.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/20354931/pubmed\" target=\"_blank\" id=\"20354931\">20354931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12605115\"></a>Marvin MR, Droogan C, Sawinski D, Cohen DJ, Hardy MA. Administration of rabbit antithymocyte globulin (thymoglobulin) in ambulatory renal-transplant patients. <i>Transplantation</i>. 2003;75(4):488-489.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/12605115/pubmed\" target=\"_blank\" id=\"12605115\">12605115</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10424515\"></a>Palmer SM, Miralles AP, Lawrence CM, et al. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. <i>Chest</i>. 1999;116(1):127-133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/10424515/pubmed\" target=\"_blank\" id=\"10424515\">10424515</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12023634\"></a>Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosingbased on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. <i>Transplantation</i>. 2002;73(9):1514-1518.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/12023634/pubmed\" target=\"_blank\" id=\"12023634\">12023634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15888051\"></a>Reyes J, Mazariegos GV, Abu-Elmagd K, et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). <i>Am J Transplant</i>. 2005;5(6):1430-1436.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/15888051/pubmed\" target=\"_blank\" id=\"15888051\">15888051</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23892326\"></a>Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. <i>Bone Marrow Transplant</i>. 2014;49(2):168-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/23892326/pubmed\" target=\"_blank\" id=\"23892326\">23892326</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thymoglobulin (antithymocyte globulin [rabbit]) [prescribing information]. Cambridge, MA: Genzyme Corporation; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23026616\"></a>Trevizol AP, David AI, Dias ER, Mantovani D, P&eacute;cora R, D'Albuquerque LA. Intestinal and multivisceral transplantation immunosuppression protocols--literature review. <i>Transplant Proc</i>. 2012;44(8):2445-2448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/23026616/pubmed\" target=\"_blank\" id=\"23026616\">23026616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22895613\"></a>Trofe-Clark J, Reese PP, Patel HJ, et al. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes. <i>Transplantation</i>. 2012;94(5):506-512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/22895613/pubmed\" target=\"_blank\" id=\"22895613\">22895613</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18475186\"></a>Vianna RM, Mangus RS, Fridell JA, Weigman S, Kazimi M, Tector J. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. <i>Transplantation</i>. 2008;85(9):1290-1293.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/18475186/pubmed\" target=\"_blank\" id=\"18475186\">18475186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26723083\"></a>Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. <i>Lancet Oncol</i>. 2016;17(2):164-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/26723083/pubmed\" target=\"_blank\" id=\"26723083\">26723083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25363471\"></a>Zuckermann A, Schulz U, Deuse T, et al. Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression. <i>Transpl Int</i>. 2015;28(3):259-269.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/25363471/pubmed\" target=\"_blank\" id=\"25363471\">25363471</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10026 Version 125.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708632\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135993\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F20858411\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F136005\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F135994\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F136002\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F135995\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46276611\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46276612\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F26416857\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F639201\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135985\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F135975\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F135987\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F135986\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25721920\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9885364\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135981\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135990\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135979\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298764\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218046\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F639176\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21098383\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F135983\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F135978\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F135989\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322995\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038531\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10026|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=antithymocyte-globulin-rabbit-derived-thymoglobulin-patient-drug-information\" class=\"drug drug_patient\">Antithymocyte globulin (rabbit derived, Thymoglobulin): Patient drug information</a></li><li><a href=\"topic.htm?path=antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information\" class=\"drug drug_pediatric\">Antithymocyte globulin (rabbit derived, Thymoglobulin): Pediatric drug information</a></li></ul></div></div>","javascript":null}